| [1] |
Bian S, Wang Y, Zhou Y, et al. Integrative single-cell multiomics analyses dissect molecular signatures of intratumoral heterogeneities and differentiation states of human gastric cancer[J]. Natl Sci Rev, 2023, 10(6): nwad094.
|
| [2] |
Zeng Y, Jin RU. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3): 566-582.
|
| [3] |
Angerilli V, Pennelli G, Galuppini F, et al. Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes[J]. Virchows Arch, 2022, 481(4): 545-552.
|
| [4] |
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517): 202-209.
|
| [5] |
Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes[J]. Nat Med, 2015, 21(5): 449-456.
|
| [6] |
Wang Q, Xie Q, Liu Y, et al. Clinical characteristics and prognostic significance of TCGA and ACRG classification in gastric cancer among the Chinese population[J]. Mol Med Rep, 2020, 22(2): 828-840.
|
| [7] |
Tirino G, Pompella L, Petrillo A, et al. What’s new in gastric cancer: the therapeutic implications of molecular classifications and future perspectives[J]. Int J Mol Sci, 2018, 19(9): 2659.
|
| [8] |
Katona BW, Rustgi AK. Gastric cancer genomics: advances and future directions[J]. Cell Mol Gastroenterol Hepatol, 2017, 3(2): 211-217.
|
| [9] |
Ooi A, Oyama T, Nakamura R, et al. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization[J]. Hum Pathol, 2017, 61: 58-67.
|
| [10] |
Mathiak M, Warneke VS, Behrens HM, et al. Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: urgent need for standardization[J]. Appl Immunohistochem Mol Morphol, 2017, 25(1): 12-24.
|
| [11] |
Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project[J]. Clin Cancer Res, 2017, 23(15): 4441-4449.
|
| [12] |
Corso S, Giordano S. How can gastric cancer molecular profiling guide future therapies?[J]. Trends Mol Med, 2016, 22(7): 534-544.
|
| [13] |
Jia X, Chen B, Li Z, et al. Identification of a Four-Gene-Based SERM Signature for prognostic and drug sensitivity prediction in gastric cancer[J]. Front Oncol, 2021, 11: 799223.
|
| [14] |
Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: A meta-analysis of randomized clinical trials[J]. ESMO Open, 2021, 6(1): 100036.
|
| [15] |
Yohe S, Thyagarajan B. Review of clinical next-generation sequencing[J]. Arch Pathol Lab Med, 2017, 141(11): 1544-1557.
|
| [16] |
Deng G, Zhang X, Chen Y, et al. Single-cell transcriptome sequencing reveals heterogeneity of gastric cancer: progress and prospects[J]. Front Oncol, 2023, 13: 1074268.
|
| [17] |
Zhang M, Hu S, Min M, et al. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing[J]. Gut, 2021, 70(3): 464-475.
|
| [18] |
Baniak N, Senger JL, Ahmed S, et al. Gastric biomarkers: A global review[J]. World J Surg Oncol, 2016, 14(1): 212.
|
| [19] |
Kim R, An M, Lee H, et al. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer[J]. Cancer Discov, 2022, 12(4): 984-1001.
|
| [20] |
Chen Y, Cheng WY, Shi H, et al. Classifying gastric cancer using FLORA reveals clinically relevant molecular subtypes and highlights LINC01614 as a biomarker for patient prognosis[J]. Oncogene, 2021, 40(16): 2898-2909.
|
| [21] |
Grady WM, Yu M, Markowitz SD. Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer[J]. Gastroenterology, 2021, 160(3): 690-709.
|
| [22] |
Pfeifer GP. Defining driver DNA methylation changes in human cancer[J]. Int J Mol Sci, 2018, 19(4): 1166.
|
| [23] |
Lian Q, Wang B, Fan L, et al. DNA methylation data-based molecular subtype classification and prediction in patients with gastric cancer[J]. Cancer Cell Int, 2020, 20: 349.
|
| [24] |
Weng S, Li M, Deng J, et al. Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer[J]. Clin Epigenetics, 2023, 15(1): 64.
|
| [25] |
Sato Y, Wada I, Odaira K, et al. Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells[J]. Clin Transl Immunology, 2020, 9(10): e1194.
|
| [26] |
Ramos M, Pereira MA, de Mello ES, et al. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: analysis in western patients after curative-intent surgery[J]. World J Clin Oncol, 2021, 12(8): 688-701.
|
| [27] |
Carneiro P, Fernandes MS, Figueiredo J, et al. E-cadherin dysfunction in gastric cancer--cellular consequences, clinical applications and open questions[J]. FEBS Lett, 2012, 586(18): 2981-2989.
|
| [28] |
Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer[J]. J Clin Oncol, 2013, 31(7): 868-875.
|
| [29] |
Cheng N, Hui DY, Liu Y, et al. Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms[J]. Gastric Cancer, 2015, 18(2): 246-255.
|
| [30] |
Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1[J]. Oncologist, 2019, 24(1): 103-109.
|
| [31] |
Mehta R, Shah A, Almhanna K. Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: An evidence-based review of place in therapy[J]. Onco Targets Ther, 2018, 11: 6525-6537.
|